Evercore ISI assumed coverage on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) in a research report report published on Tuesday morning, MarketBeat.com reports. The firm issued an outperform rating and a $14.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on DRNA. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a strong sell rating to a buy rating and set a $6.25 target price for the company in a report on Monday, October 23rd. ValuEngine upgraded Dicerna Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, November 2nd. HC Wainwright reiterated a buy rating and issued a $10.00 target price (up from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. Finally, BidaskClub cut Dicerna Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, January 9th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $8.25.

Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) traded down $0.14 during mid-day trading on Tuesday, hitting $8.83. The company’s stock had a trading volume of 162,057 shares, compared to its average volume of 339,531. Dicerna Pharmaceuticals has a twelve month low of $2.42 and a twelve month high of $10.24. The stock has a market cap of $456.00, a PE ratio of -2.57 and a beta of 2.84.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.22). Dicerna Pharmaceuticals had a negative return on equity of 293.25% and a negative net margin of 5,895.26%. The firm had revenue of $0.47 million during the quarter. During the same period last year, the company earned ($0.68) EPS. The company’s revenue for the quarter was up 192.6% on a year-over-year basis. equities analysts anticipate that Dicerna Pharmaceuticals will post -2.93 earnings per share for the current fiscal year.

In related news, Director Bain Capital Life Sciences Inv purchased 285,000 shares of Dicerna Pharmaceuticals stock in a transaction dated Monday, December 18th. The stock was purchased at an average cost of $7.00 per share, with a total value of $1,995,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 29.41% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northern Trust Corp raised its position in shares of Dicerna Pharmaceuticals by 6.1% in the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 2,094 shares in the last quarter. Birchview Capital LP raised its position in shares of Dicerna Pharmaceuticals by 125.0% in the 3rd quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock worth $259,000 after acquiring an additional 25,000 shares in the last quarter. Deschutes Portfolio Strategy LLC bought a new position in shares of Dicerna Pharmaceuticals in the 3rd quarter worth $575,000. Vanguard Group Inc. raised its position in shares of Dicerna Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after acquiring an additional 14,517 shares in the last quarter. Finally, Palo Alto Investors LLC raised its position in shares of Dicerna Pharmaceuticals by 4.0% in the 2nd quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock worth $1,588,000 after acquiring an additional 19,394 shares in the last quarter. 21.93% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.thecerbatgem.com/2018/01/19/dicerna-pharmaceuticals-drna-receives-new-coverage-from-analysts-at-evercore-isi.html.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.